The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System (SUNRISE)

Patients suffering of an intracranial aneurysm and necessitating an endovascular treatment.

Patients who meet all of the general inclusion criteria and none of the exclusion criteria and who agree to voluntarily sign a informed consent form will be enrolled into the study.

Inclusion Criteria:

• The subject must be >= 18 years of age and less than 80 years.
• Diagnosis of a ruptured (Hunt and Hess Grade I - III) or unruptured intracranial aneurysm at the time of the treatment
• Subject (or his/her legal representative) provides written informed consent for the use of his/her peri-procedural and follow-up data

Exclusion Criteria:

• Diagnosis of Hunt and Hess Grade IV or V subarachnoid hemorrhage at the time of the treatment
• Severe co-morbidity associated with a life-expectancy of less than six months
• Poor neurological status at baseline
• Known allergies to Nitinol metal
• Known allergies to aspirin, heparin, ticlopidine, or clopidogrel or unable or unwilling to tolerate therapy
• Participation in an investigational drug or another device study is only allowed after written approval of the coordinating investigator or Cordis Medical Monitor.
• Implantation of an intracranial stent associated with the symptomatic distribution within 12 weeks prior to the index procedure
• Implantation of carotid stent associated with the symptomatic distribution within 12 weeks prior to the index procedure
• Atrial fibrillation or known cardiac disorders likely to be associated with cardioembolic symptoms.